VINC (Vincerx Pharma) FCF Margin %: 0.00% (As of Mar. 2025)


What is Vincerx Pharma FCF Margin %?

Vincerx Pharma VINC FCF Margin % is 0.00% as of Mar. 2025.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vincerx Pharma's Free Cash Flow for the three months ended in Mar. 2025 was $-4.45 Mil. Vincerx Pharma's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, Vincerx Pharma's FCF Margin % for the quarter that ended in Mar. 2025 was 0.00%.

As of today, Vincerx Pharma's current FCF Yield % is -34,609.09%.

The historical rank and industry rank for Vincerx Pharma's FCF Margin % or its related term are showing as below:


VINC's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Vincerx Pharma FCF Margin % Related Terms

Vincerx Pharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for Vincerx Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vincerx Pharma FCF Margin % Chart

Vincerx Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Vincerx Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VINC vs SYGGF, CNBX, LADX: FCF Margin % Comparison

For the Biotechnology subindustry, Vincerx Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vincerx Pharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vincerx Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vincerx Pharma's FCF Margin % falls into.


Vincerx Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vincerx Pharma's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-26.127/0
= %

Vincerx Pharma's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-4.454/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Vincerx Pharma (VINC) has a FCF Margin % of 0.00% as of Mar. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vincerx Pharma and its competitors.
Is Vincerx Pharma's FCF Margin % too high?
Vincerx Pharma's current FCF Margin % is 0.00%.
How does Vincerx Pharma's FCF Margin % compare to SYGGF and CNBX?
Vincerx Pharma's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vincerx Pharma and its competitors. Vincerx Pharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vincerx Pharma stock overvalued right now?
Vincerx Pharma (VINC) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Vincerx Pharma (VINC), the current FCF Margin % is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vincerx Pharma Business Description

Address 1825 S. Grant Street, San Mateo, CA, USA, 94402
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.